Neomycin and Polymyxin B Sulfates and
Dexamethasone Ophthalmic Suspension is a multiple dose anti-infective
steroid combination in a sterile suspension for topical application.
Neomycin Sulfate is the sulfate salt of neomycin B and C which are produced by the growth of Streptomyces fradiae Waksman. It has a potency equivalent to not less than 600 micrograms of neomycin base per milligram, calculated on an anhydrous basis.
Polymyxin B Sulfate is the sulfate salt of Polymyxin B1 and B2 which are produced by the growth of Bacillus polymyxa Migula. It has a potency of not less than 6,000 Polymyxin B units per milligram, calculated on an anhydrous basis.
Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Topical ocular administration of % dexamethasone ( mg/kg/day) on gestational days 10 to 13 produced embryofetal lethality and a high incidence of cleft palate in mice. A dose of mg/kg/day in the mouse is approximately 3 times an OZURDEX ® injection in humans ( mg dexamethasone) on a mg/m2 basis. In rabbits, topical ocular administration of % dexamethasone throughout organogenesis ( mg/kg/day, on gestational day 6 followed by mg/kg/day on gestational days 7-18) produced intestinal anomalies, intestinal aplasia, gastroschisis and hypoplastic kidneys. A dose of mg/kg/day in the rabbit is approximately 4 times an OZURDEX ® injection in humans ( mg dexamethasone) on a mg/m2 basis.